Fred Hutchinson Cancer Research Center researchers have identified a mutation of double homeobox 4 that could be targeted in facioscapulohumeral muscular dystrophy. The team has partnered with GlaxoSmithKline to develop small molecule inhibitors against DUX4 or its downstream effectors.